These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 37058483)

  • 1. Activity of luspatercept and ESAs combination for treatment of anemia in lower-risk myelodysplastic syndromes.
    Komrokji RS; Aguirre LE; Al Ali NH; Chan O; Xie Z; Kuykendall A; Sweet K; Lancet JE; Padron E; Sallman DA
    Blood Adv; 2023 Jul; 7(14):3677-3679. PubMed ID: 37058483
    [No Abstract]   [Full Text] [Related]  

  • 2. Luspatercept in Myelodysplastic Syndromes: Who and When?
    Komrokji RS
    Hematol Oncol Clin North Am; 2020 Apr; 34(2):393-400. PubMed ID: 32089218
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Luspatercept: First Approval.
    Markham A
    Drugs; 2020 Jan; 80(1):85-90. PubMed ID: 31939073
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Luspatercept use for lower risk myelodysplastic syndromes: Active but not enough.
    Patnaik MM; Tefferi A
    Am J Hematol; 2023 Aug; 98(8):1171-1175. PubMed ID: 37345627
    [No Abstract]   [Full Text] [Related]  

  • 5. Luspatercept in low-risk myelodysplastic syndromes: a paradigm shift in treatment strategies.
    Molica M; Rossi M
    Expert Opin Biol Ther; 2024 Apr; 24(4):233-241. PubMed ID: 38555469
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Myelo-deception: Luspatercept & TGF-Beta ligand traps in myeloid diseases & anemia.
    Feld J; Navada SC; Silverman LR
    Leuk Res; 2020 Oct; 97():106430. PubMed ID: 32763582
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Luspatercept for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes (PACE-MDS): a multicentre, open-label phase 2 dose-finding study with long-term extension study.
    Platzbecker U; Germing U; Götze KS; Kiewe P; Mayer K; Chromik J; Radsak M; Wolff T; Zhang X; Laadem A; Sherman ML; Attie KM; Giagounidis A
    Lancet Oncol; 2017 Oct; 18(10):1338-1347. PubMed ID: 28870615
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes.
    Fenaux P; Platzbecker U; Mufti GJ; Garcia-Manero G; Buckstein R; Santini V; Díez-Campelo M; Finelli C; Cazzola M; Ilhan O; Sekeres MA; Falantes JF; Arrizabalaga B; Salvi F; Giai V; Vyas P; Bowen D; Selleslag D; DeZern AE; Jurcic JG; Germing U; Götze KS; Quesnel B; Beyne-Rauzy O; Cluzeau T; Voso MT; Mazure D; Vellenga E; Greenberg PL; Hellström-Lindberg E; Zeidan AM; Adès L; Verma A; Savona MR; Laadem A; Benzohra A; Zhang J; Rampersad A; Dunshee DR; Linde PG; Sherman ML; Komrokji RS; List AF
    N Engl J Med; 2020 Jan; 382(2):140-151. PubMed ID: 31914241
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Luspatercept in the treatment of lower-risk myelodysplastic syndromes.
    Chan O; Komrokji RS
    Future Oncol; 2021 Apr; 17(12):1473-1481. PubMed ID: 33511859
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Population Pharmacokinetics and Exposure-Response of Luspatercept, an Erythroid Maturation Agent, in Anemic Patients With Myelodysplastic Syndromes.
    Chen N; Kassir N; Laadem A; Maxwell SE; Sriraman P; Giuseppi AC; Ritland S; Linde PG; Budda B; Reynolds JG; Zhou S; Palmisano M
    CPT Pharmacometrics Syst Pharmacol; 2020 Jul; 9(7):395-404. PubMed ID: 32602651
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New Approaches for Anemia in MDS.
    Platzbecker U
    Clin Lymphoma Myeloma Leuk; 2020 Sep; 20 Suppl 1():S59-S60. PubMed ID: 32862871
    [No Abstract]   [Full Text] [Related]  

  • 12. The prognostic value of serum erythropoietin in patients with lower-risk myelodysplastic syndromes: a review of the literature and expert opinion.
    Park S; Kelaidi C; Meunier M; Casadevall N; Gerds AT; Platzbecker U
    Ann Hematol; 2020 Jan; 99(1):7-19. PubMed ID: 31650290
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Luspatercept: A Review in Transfusion-Dependent Anaemia due to Myelodysplastic Syndromes or β-Thalassaemia.
    Kang C; Syed YY
    Drugs; 2021 Jun; 81(8):945-952. PubMed ID: 33970460
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Is luspatercept the new standard of care in transfusion-dependent low-risk myelodysplastic syndromes?
    Garcia-Manero G
    Clin Adv Hematol Oncol; 2024 Oct; 22(8):367-369. PubMed ID: 39356814
    [No Abstract]   [Full Text] [Related]  

  • 15. New drugs for myeloid neoplasms with ring sideroblasts: Luspatercept vs imetelstat.
    Tefferi A
    Am J Hematol; 2021 Jul; 96(7):761-763. PubMed ID: 33861878
    [No Abstract]   [Full Text] [Related]  

  • 16. Real-world efficacy and safety of luspatercept and predictive factors of response in patients with lower risk myelodysplastic syndromes with ring sideroblasts.
    Lanino L; Restuccia F; Perego A; Ubezio M; Fattizzo B; Riva M; Consagra A; Musto P; Cilloni D; Oliva EN; Palmieri R; Poloni A; Califano C; Capodanno I; Itri F; Elena C; Fozza C; Pane F; Pelizzari AM; Breccia M; Di Bassiano F; Crisà E; Ferrero D; Giai V; Barraco D; Vaccarino A; Griguolo D; Minetto P; Quintini M; Paolini S; Sanpaolo G; Sessa M; Bocchia M; Di Renzo N; Diral E; Leuzzi L; Genua A; Guarini A; Molteni A; Nicolino B; Occhini U; Rivoli G; Bono R; Calvisi A; Castelli A; Di Bona E; Di Veroli A; Ferrara F; Fianchi L; Galimberti S; Grimaldi D; Marchetti M; Norata M; Frigeni M; Sancetta R; Selleri C; Tanasi I; Tosi P; Turrini M; Giordano L; Finelli C; Pasini P; Naldi I; Santini V; Della Porta MG;
    Am J Hematol; 2023 Aug; 98(8):E204-E208. PubMed ID: 37222267
    [No Abstract]   [Full Text] [Related]  

  • 17. Luspatercept for the treatment of anemia in myelodysplastic syndromes and primary myelofibrosis.
    Fenaux P; Kiladjian JJ; Platzbecker U
    Blood; 2019 Feb; 133(8):790-794. PubMed ID: 30602619
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Luspatercept as a therapy for myelodysplastic syndromes with ring sideroblasts.
    Schulz F; Nachtkamp K; Kasprzak A; Gattermann N; Haas R; Germing U
    Expert Rev Hematol; 2021 Jun; 14(6):509-516. PubMed ID: 34161752
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Luspatercept for myelodysplastic syndromes/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis.
    Komrokji RS; Platzbecker U; Fenaux P; Zeidan AM; Garcia-Manero G; Mufti GJ; Santini V; Díez-Campelo M; Finelli C; Jurcic JG; Greenberg PL; Sekeres MA; DeZern AE; Savona MR; Shetty JK; Ito R; Zhang G; Ha X; Backstrom JT; Verma A
    Leukemia; 2022 May; 36(5):1432-1435. PubMed ID: 35220402
    [No Abstract]   [Full Text] [Related]  

  • 20. Neutrophil and platelet increases with luspatercept in lower-risk MDS: secondary endpoints from the MEDALIST trial.
    Garcia-Manero G; Mufti GJ; Fenaux P; Buckstein R; Santini V; Díez-Campelo M; Finelli C; Ilhan O; Sekeres MA; Zeidan AM; Ito R; Zhang J; Rampersad A; Sinsimer D; Backstrom JT; Platzbecker U; Komrokji RS
    Blood; 2022 Jan; 139(4):624-629. PubMed ID: 34758066
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.